Predicting Survival in Pulmonary Arterial Hypertension

Прогнозирование выживаемости при легочной артериальной гипертензии
Raymond L. Benza, Dave P. Miller, Mardi Gomberg‐Maitland, Robert P. Frantz, Aimee J. Foreman, Christopher S. Coffey, Adaani Frost, Robyn J. Barst, David B. Badesch, C. Gregory Elliott, Theodore G. Liou, Michael D. McGoon
2010-06-29

Cox proportional hazardsREVEAL Registryprognostic equationpulmonary arterial hypertensionsurvival prediction
BACKGROUND: Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use. METHODS AND RESULTS: Data from 2716 patients with PAH enrolled consecutively in the US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess predictors of 1-year survival. We identified independent prognosticators of survival and derived a multivariable, weighted risk formula for clinical use. One-year survival from the date of enrollment was 91.0% (95% confidence interval [CI], 89.9 to 92.1). In a multivariable analysis with Cox proportional hazards, variables independently associated with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4.1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modified New York Heart Association/World Health Organization functional class IV (HR, 3.1; 95% CI, 2.2 to 4.4), men >60 years of age (HR, 2.2; 95% CI, 1.6 to 3.0), and family history of PAH (HR, 2.2; 95% CI, 1.2 to 4.0). Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality. Based on these multivariable analyses, a prognostic equation was derived and validated by bootstrapping technique. CONCLUSIONS: We identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00370214.
1
A REVEAL Registry cohort of 2,716 patients with pulmonary arterial hypertension was analyzed to identify predictors of 1-year survival.
2
Independent predictors of increased mortality included pulmonary vascular resistance >32 Wood units, portal-hypertension-associated PAH, functional class IV, male age >60 years, and family history of PAH.
3
Overall 1-year survival from enrollment was 91.0% (95% CI, 89.9–92.1).
4
Renal insufficiency, connective-tissue-disease-associated PAH, functional class III, hemodynamic measures, exercise capacity, biomarkers, diffusing capacity, and pericardial effusion also predicted mortality.
5
The study derived and bootstrap-validated a weighted prognostic equation intended to individualize treatment strategies, while emphasizing serial follow-up and reassessment.

Patients with pulmonary arterial hypertension (PAH) enrolled in the US REVEAL registry

Predictors of 1-year survival and the multivariable prognostic risk relationship in PAH

Publication Details
Publication Date
2010-06-29
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Raymond L. Benza
Dave P. Miller
Mardi Gomberg‐Maitland
Robert P. Frantz
Aimee J. Foreman
Christopher S. Coffey
Adaani Frost
Robyn J. Barst
David B. Badesch
C. Gregory Elliott
Theodore G. Liou
Michael D. McGoon
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%